Five debt-free stocks trading at premium valuations: are they worth the price?

Investors must therefore assess whether a company's growth prospects justify the price its shares command. This article examines five low-debt stocks trading at premium valuations. This is not a stock recommendation. Divi's Laboratories is one of India's leading pharmaceutical manufacturers, supplying active pharmaceutical ingredients (APIs), intermediates and custom synthesis products to global pharmaceutical companies.

The company has a debt-to-equity ratio of zero, giving it a debt-free balance sheet and reducing its exposure to interest costs. However, its valuation multiples are significantly higher than those of the broader healthcare sector. Divi's trades at a price-to-earnings (PE) multiple of 86, against 42.3 for the BSE Healthcare index. Its price-to-book (PB) ratio of 13.6 is also well above the sector's 7.49, indicating that investors are paying a substantial premium for its earnings and assets.

In the first quarter of fiscal year (FY27), the company reported consolidated total income of ₹31.44 billion, compared with ₹25.29 billion in the year-earlier period. Profit after tax rose to ₹9.02 billion from ₹5.45 billion. Management said the external operating environment remained challenging during the quarter, particularly across global trade routes and sourcing channels linked to West Asia.

Raw material availability remained largely stable, although input cost trends varied across categories. Peptides remain a strategic investment area. Customer programmes continued to progress across multiple stages of development in Q1FY27, while qualification and validation activities for several peptide fragments are expected to advance over the coming quarters. Alongside capacity expansion in solid-phase and liquid-phase peptide synthesis, Divi's is strengthening its process development, analytical and manufacturing capabilities to handle increasingly complex peptide chemistry.

Unit 3 also continues to play a major role in the company's production network. The facility supports its backward integration strategy through selected pre-chemistry operations and enables the phased transfer of manufacturing activities from existing facilities. Trent is a Tata Group company with a strong presence in India's organised retail market through its Westside and Zudio formats, which cater to different consumer segments.

Trent has a debt-to-equity ratio of zero. However, its valuation multiples are significantly higher than those of the Nifty 50 index, of which it is a constituent. The stock trades at a PE multiple of 82.4, compared with 19.2 for the Nifty 50. Its PB ratio of 20 is also substantially higher than the index's aggregate PB of 2.79. It commands a premium even over peers such as Arvind Fashions. In Q1FY27, Trent reported revenue of ₹57.55 billion, up 18% year-on-year (YoY), while net profit rose 22% to ₹5.18 billion.

The company opened one Westside and 22 Zudio stores during the quarter, including one Zudio outlet in the UAE. It also consolidated three Zudio stores and expanded its presence to nine new cities. As of 30 June, its retail portfolio comprised 301 Westside stores, 982 Zudio stores, including seven in the UAE, and 29 outlets across other lifestyle concepts. Its fashion brands had a combined footprint of more than 18 million sq. ft.

Looking ahead, Trent plans to add stores in select existing catchments across Tier I and Tier II cities while accelerating its expansion into smaller markets. More than 80% of the Zudio stores opened in Q1FY27 were in tier II and tier III cities and emerging peripheral micro-markets. The company aims to deepen its presence in existing markets while entering new micro-markets and geographies. Its strategy is to expand reach and revenue share by selectively increasing store density in key markets and strengthening its customer proposition.

SBI Life Insurance is one of India's largest private-sector life insurers, offering protection, savings, retirement, child education and market-linked investment products. State Bank of India is its promoter. The company has a debt-free balance sheet but trades at a substantial premium to the Nifty 50's PE and PB multiples. Its valuation is also higher than those of peers such as HDFC Life Insurance and ICICI Prudential Life Insurance, which trade at PE multiples of 58 and 33.6, respectively.

SBI Life reported strong growth in new business during Q1FY27. New business premium rose 23% to ₹89.1 billion, giving it a 20.5% share of the private life insurance market. Individual rated new business premium increased 14% YoY to ₹39.7 billion, with a private market share of 22.2%. Gross written premium rose 20% to ₹212.9 billion. Net profit grew 22% to ₹7.2 billion. Value of new business (VNB), which measures the expected profit from policies sold during a particular period, rose 29% to ₹14.1 billion.

The metric helps investors assess whether an insurer is generating profitable growth rather than merely expanding sales. SBI Life's VNB margin stood at 26.2% in Q1FY27. Its Indian embedded value as of 30 June 2026 was ₹852.9 billion. Management remains confident about the long-term growth potential of India's life insurance sector and the company's ability to navigate an evolving market while maintaining its focus on profitable and sustainable growth.

Pidilite Industries is one of India's leading manufacturers of adhesives, sealants, construction chemicals and do-it-yourself products. Its best-known brands include Fevicol, Fevikwik, Dr Fixit and M-Seal. Pidilite has a debt-free balance sheet but trades at a substantial premium to the BSE 500's PE and PB multiples. Its PE valuation is also higher than those of several companies in the chemicals sector.

The company reported consolidated revenue of ₹45.41 billion in Q1FY27, up 21.3% YoY. EBITDA margin improved by 120 basis points from a year earlier, while profit after tax grew 30.3%. Growth across its international subsidiaries was reasonably broad-based, with Bangladesh, Egypt and Kenya recording stronger growth than in previous periods. However, total exports declined during the quarter, largely because of geopolitical disruptions in some of Pidilite's key markets.

While its established brands and opportunities for market expansion support the growth outlook, volatile crude-linked raw material prices, geopolitical tensions and competition remain potential risks to margins. Titan is a Tata Group company and a leading player in India's lifestyle and branded jewellery markets. Its jewellery portfolio includes Tanishq, CaratLane, Mia and Zoya, while its watch brands include Titan, Sonata, Fastrack and Nebula.

The company also operates in eyewear through Titan Eye+, fragrances through SKINN and ethnic wear through Taneira. Titan has a debt-to-equity ratio of zero and trades at a PE multiple of 67.3. This is a substantial premium to the Nifty 50 and competitors such as Kalyan Jewellers, which trades at a PE of around 36. However, Titan has a significantly larger and more diversified business. The company began FY27 on a strong note, with its consumer businesses recording 40% YoY growth in Q1.

Management attributed the performance to innovation and design-led differentiation across its jewellery, watches, eyewear and emerging businesses. However, the quarter also required agility in navigating higher gold prices, sharp changes in the duty structure and geopolitical headwinds affecting international operations. One factor that investors should watch is the improvement in the jewellery division's earnings before interest and tax (Ebit) margin.

Management said mark-to-market (MTM) gains on inventory contributed 75-80 basis points to the margin in Q1FY27. This benefit is unlikely to be sustained and could reverse in subsequent quarters. After adjusting for both the customs duty benefit and the MTM gain, management said the normalized EBIT margin for the Tanishq, Mia and Zoya businesses would have been 10.9% during the quarter. Titan's premium valuation leaves limited room for disappointment.

Slower jewellery demand, rising gold prices, margin pressures or intensifying competition could weigh on earnings growth. A debt-free balance sheet can provide financial stability and give companies greater flexibility to pursue growth. But low debt alone does not make a stock attractive, particularly when its valuation already factors in strong future performance. Even fundamentally sound businesses can face sharp share-price corrections if earnings growth slows, competition intensifies or market sentiment weakens.

Investors should therefore examine cash flows, return ratios, earnings consistency and business prospects alongside valuation multiples before making investment decisions. Reasonable entry prices and appropriate risk management remain essential, as past performance does not guarantee future returns. This article is syndicated from Equitymaster.com